PFE logo Pfizer +
Pfizer
+

Pfizer (PFE) Business News

Track Pfizer in real time with a live news feed covering Pfizer stock news, official press releases, company announcements, and an archive of historical Pfizer news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
2:00 PM | Tuesday | Jul 14, 2026 Fool - Investing News

3 of the Best Stocks to Buy for Less Than $100 Right Now

News Thumbnail
11:51 AM | Tuesday | Jul 14, 2026 24/7 Wall Street

Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen

News Thumbnail
11:31 AM | Tuesday | Jul 14, 2026 Zacks Investment Research

Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results

News Thumbnail
10:24 AM | Tuesday | Jul 14, 2026 Fool - Investing News

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

News Thumbnail
5:00 AM | Tuesday | Jul 14, 2026 The Motley Fool

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

News Thumbnail
11:51 AM | Tuesday | Jul 14, 2026 24/7 Wall Street

Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen

News Thumbnail
11:31 AM | Tuesday | Jul 14, 2026 Zacks Investment Research

Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results

News Thumbnail
10:24 AM | Tuesday | Jul 14, 2026 Fool - Investing News

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

News Thumbnail
5:00 AM | Tuesday | Jul 14, 2026 The Motley Fool

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

News Thumbnail
12:25 PM | Monday | Jul 13, 2026 MarketBeat

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

News Thumbnail
8:15 AM | Saturday | Jul 11, 2026 Seeking Alpha

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (July 2026)

News Thumbnail
7:09 AM | Saturday | Jul 11, 2026 Seeking Alpha

Pfizer: The AI Hedge That Pays You To Stay Defensive

News Thumbnail
6:01 AM | Saturday | Jul 11, 2026 Seeking Alpha

July Graham Value All-Stars (GVAS) Emit 10 Beaming Buys

News Thumbnail
5:45 AM | Saturday | Jul 11, 2026 Seeking Alpha

Pfizer: The Post-Pandemic Turnaround Is Already Underway

News Thumbnail
11:23 AM | Friday | Jul 10, 2026 Business Wire

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

News Thumbnail

3 of the Best Stocks to Buy for Less Than $100 Right Now

Fool - Investing News

2:00 PM | Tuesday | Jul 14, 2026

news photo
Loading...

These stocks offer a good mix of dividends, growth, and long-term stability.

Read full article redirect
2:00 PM | Tuesday | Jul 14, 2026

3 of the Best Stocks to Buy for Less Than $100 Right Now

Fool - Investing News

These stocks offer a good mix of dividends, growth, and long-term stability.

Read full article arrow
News Thumbnail
11:51 AM | Tuesday | Jul 14, 2026

Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen

24/7 Wall Street

Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.

Read full article arrow
News Thumbnail
11:31 AM | Tuesday | Jul 14, 2026

Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results

Zacks Investment Research

PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.

Read full article arrow
News Thumbnail
10:24 AM | Tuesday | Jul 14, 2026

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

Fool - Investing News

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

Read full article arrow
News Thumbnail
5:00 AM | Tuesday | Jul 14, 2026

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

The Motley Fool

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.

Read full article arrow
News Thumbnail
11:51 AM | Tuesday | Jul 14, 2026

Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen

24/7 Wall Street

Pfizer (NYSE: PFE | PFE Price Prediction) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology.

Read full article arrow
News Thumbnail
11:31 AM | Tuesday | Jul 14, 2026

Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results

Zacks Investment Research

PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.

Read full article arrow
News Thumbnail
10:24 AM | Tuesday | Jul 14, 2026

Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?

Fool - Investing News

The pharma giant's yield of around 7.1% is more than six times the S&P 500 average.

Read full article arrow
News Thumbnail
5:00 AM | Tuesday | Jul 14, 2026

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

The Motley Fool

Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.

Read full article arrow
News Thumbnail
12:25 PM | Monday | Jul 13, 2026

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

MarketBeat

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

Read full article arrow
News Thumbnail
8:15 AM | Saturday | Jul 11, 2026

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (July 2026)

Seeking Alpha

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.
1%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.

Read full article arrow
News Thumbnail
7:09 AM | Saturday | Jul 11, 2026

Pfizer: The AI Hedge That Pays You To Stay Defensive

Seeking Alpha

Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. I view PFE as a defensive holding that pays investors to maintain a cautious stance in volatile markets. PFE offers an attractive opportunity to offset AI-related risks within a broader portfolio context.

Read full article arrow
News Thumbnail
6:01 AM | Saturday | Jul 11, 2026

July Graham Value All-Stars (GVAS) Emit 10 Beaming Buys

Seeking Alpha

July's GVAS Dogs list highlights ten fair-priced, high-yield large-cap stocks, including IRSA Inversiones, Weibo, Verizon, and AT&T, as ideal buys. Analyst targets project average net gains of 40.39% for the top ten GVAS stocks by July 2027, with risk profiles generally below market volatility. The dividend dogcatcher strategy favors stocks whose $1K dividend income exceeds share price, with 36 of 54 GVAS stocks meeting this ideal condition.

Read full article arrow
News Thumbnail
5:45 AM | Saturday | Jul 11, 2026

Pfizer: The Post-Pandemic Turnaround Is Already Underway

Seeking Alpha

Pfizer is undervalued, trading at just over 8x 2026 earnings, with a 7% dividend yield and improving core business fundamentals. Core business excluding COVID drugs grew 7% in Q1, and newly launched/acquired products, especially from Seagen, are driving robust 20%+ growth. Seagen's acquisition is reshaping PFE's growth, with Padcev leading oncology momentum and a strong cost savings program underway.

Read full article arrow
News Thumbnail
11:23 AM | Friday | Jul 10, 2026

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Business Wire

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant and adjuvant (before and after surgery) treatment for adult patient.

Read full article arrow
News Thumbnail